Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00536341 | Completed Phase 1 Results

• 1 other identifier: SCRI CLL 02
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 6

Brief Summary

This phase I/II trial will combine fludarabine, rituximab, and lenalidomide in untreated or minimally treated (Phase I only) CLL patients, employing fixed doses of fludarabine and rituximab, using a schedule similar to that examined by investigators at MD Anderson (J Clin Oncol 23(18):4079-88, 2005). Given that the optimal dose and schedule is not currently known, this trial will perform a phase I component followed by a phase II examination to further explore this regimen's activity.

Conditions

Chronic Lymphocytic Leukemia

Keywords

Chronic Lymphocytic Leukemia; untreated; minimally treated; fludarabine; rituximab; lenalidomide

Outcome Measures

Primary Outcomes (2)

• Number of Adverse Events as a Measure of Safety and Tolerability

  Recorded from first treatment until 30 days after last treatment and assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

  63 months

• Complete Response Rate

  An improvement in complete response to at least 60% following treatment, assessed using CT scans, clinical/lab examinations, and bone marrow aspirations, as defined by National Cancer Institute Working Group Response Criteria.

  At 12 weeks during treatment and 2 months post-treatment until disease progression, projected 8 months

Secondary Outcomes (2)

• Progression-Free Survival

  Every 3 months during treatment until disease progression and every 6 months thereafter, up to 5 years

• Overall Survival

  Every 3 months until treatment discontinuation, expected average of 6 months and then every 6 months thereafter up to 5 years

Study Arms (1)

lenalidomide, fludarabine, rituximab

EXPERIMENTAL

Phase I Non-stratified, dose-escalation: \>=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed. Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation.

Drug: lenalidomide; Drug: Rituximab; Drug: Fludarabine

Interventions

lenalidomide DRUG

2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6

Also known as: Revlimid

lenalidomide, fludarabine, rituximab

Rituximab DRUG

375 mg/m2 Cycle 1 (split over Day 1 \& Day 2); 500 mg/m2 Day 1 of Cycles 2-6

Also known as: Rituxan

lenalidomide, fludarabine, rituximab

Fludarabine DRUG

25 mg/m2 on Days 1, 2, and 3

Also known as: Fludara

lenalidomide, fludarabine, rituximab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Understand and voluntarily sign an informed consent form.
• Able to adhere to the study visit schedule and other protocol requirements.
• Age \>=18 years at the time of signing the informed consent form.
• Patient must have histopathologically confirmed B-cell CLL
• For Phase I only: Untreated or minimally treated patients (patients who have received only prior single agent rituximab) are eligible. For those patients who have had rituximab monotherapy, last dose must be greater than 90 days prior to beginning study treatment.
• For Phase II only: Untreated B-cell CLL patients only.
• Rai staging, will be employed. Patients must have Rai stage III/IV disease (irrespective of symptoms) OR symptomatic Rai stage 0-II disease, requiring therapy as defined by NCI 1996 guidelines.
• Platelets must be \> 75,000/mm3 and absolute neutrophil count must be \> 1000/mm3 within 14 days of starting protocol treatment unless treating physicians deems the neutropenia is related to marrow involvement and then ANC \> 750/mm3 is allowed.
• Serum creatinine \<=2.0 mg/dl obtained within 14 days of starting protocol treatment. Creatinine clearance as determined by the Cockroft-Gault formula, using ideal body weight, must be \> 30 mL/minute.
• AST or ALT must be \< 3 x the upper limit of normal within 14 days of starting treatment.
• ECOG performance of 0, 1 or 2.
• Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
• Disease free of prior malignancies for \>= 2 years (including carcinoma in situ of the cervix or breast) treated with curative intent and anticipated 5 year disease-free survival is greater than 90%. Any basal cell or squamous cell carcinoma of the skin treated with curative intent is permitted.
• Able to take aspirin (325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use low molecular weight heparin).

You may not qualify if:

• Major surgery less than 28 days prior to study treatment.
• Any prior use of lenalidomide or thalidomide.
• Concurrent use of other anti-cancer therapies.
• Pregnant or breast feeding females. (Lactating females may be considered if they agree not to breast feed while receiving study treatment and until 12 months following last dose of rituximab).
• History of pulmonary embolus or deep vein thrombosis.
• Clinically significant heart dysfunction, defined as New York Heart Association class III or IV, at the time of screening, or history of myocardial infarction or heart failure within 6 months preceding the first study treatment (cardiac ejection fraction must be \>= 50% within 8 weeks of beginning study treatment for any patient with a history of clinically significant heart dysfunction).
• Known positive for HIV, hepatitis B surface Ag, hepatitis B core antibody, or hepatitis C. Mandatory testing is not required, but should be considered in patients deemed high risk or suspicious.
• Active infection requiring oral or intravenous antibiotics at study entry. After infection resolves patient may be evaluated for enrollment.
• Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.
• Richter's transformation.
• CNS involvement.
• Other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with interpretation of study results that in the judgment of the investigator would make the patient inappropriate for this study or that would prevent the patient from signing the informed consent form.
• Use of any other biologic agent or disease-modifying anti-rheumatic drugs (DMARDS).
• Known anaphylaxis or IgE-mediated hypersensitivity to murine proteins or any component of rituximab.
• Evidence of laboratory TLS by Cairo-Bishop criteria (subjects may be enrolled upon correction of electrolyte abnormalities).

Sponsors & Collaborators

• SCRI Development Innovations, LLC: lead
• Celgene Corporation: collaborator
• Genentech, Inc.: collaborator

Study Sites (6)

Florida Cancer Specialists

Fort Myers, Florida, 33901, United States

Location

Florida Hospital Cancer Institute

Orlando, Florida, 32804, United States

Location

Center for Cancer and Blood Disorders

Bethesda, Maryland, 20817, United States

Location

National Capital Clinical Research Consortium

Bethesda, Maryland, 20817, United States

Location

South Carolina Oncology Associates, PA

Columbia, South Carolina, 29210, United States

Location

Tennessee Oncology, PLLC

Nashville, Tennessee, 37023, United States

Location

Related Links

• Sarah Cannon Research Institute

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

Lenalidomide; Rituximab; fludarabine; fludarabine phosphate

Condition Hierarchy (Ancestors)

Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Phthalimides; Phthalic Acids; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Piperidones; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Isoindoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Antibodies, Monoclonal, Murine-Derived; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Results Point of Contact

• Title: John D Hainsworth, MD
• Organization: Sarah Cannon Research Institute

asksarah@scresearch.net

1-877-691-7274

Study Officials

• Ian W. Flinn, M.D.

  SCRI Development Innovations, LLC

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 24, 2007
• First Posted: September 27, 2007
• Study Start: January 1, 2008
• Primary Completion: April 1, 2013
• Study Completion: November 1, 2016
• Last Updated: January 16, 2017
• Results First Posted: May 4, 2016

Record last verified: 2016-11

Locations

US (6)